In this issue:
First-line BRAF/MEK inhibitors vs anti-PD-1 monotherapy in BRAF V600-mutant advanced melanoma
ICIs retain effectiveness in older patients with cutaneous metastatic melanoma
Nodal recurrence is a primary driver of early relapse for SLN-positive melanoma
Nomograms to predict local, regional, and distant recurrence in patients with thin melanomas
Impact of shave biopsy on management of cutaneous melanoma
Patient experience of see-and-treat melanoma clinic
Skin cancer and melanoma risk scores for population screening
Response to ICI rechallenge after high-grade irAEs in advanced melanoma
BRAF inhibitor treatment is feasible in elderly advanced melanoma patients
Please login below to download this issue (PDF)